SEC Info - AC Immune SA - ‘6-K’ for 9/26/22

SEC Info℠

Home

Help

Please Sign In

AC Immune SA – ‘6-K’ for 9/26/22

On: Monday, 9/26/22, at 9:07am ET · For: 9/26/22 · Accession #: 950103-22-16378 · File #: 1-37891

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 9/26/22  AC Immune SA                      6-K         9/26/22    2:975K                                   Davis Polk & … LLP 01/FA

Current, Quarterly or Annual Report by a Foreign Issuer — Form 6-K — SEA’34

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 6-K         Current, Quarterly or Annual Report by a Foreign    HTML     12K 
                Issuer                                                           
 2: EX-99.1     Miscellaneous Exhibit                               HTML     22K

‘6-K’ — Current, Quarterly or Annual Report by a Foreign Issuer

This is an HTML Document rendered as filed. [ Alternative Formats ]

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of September, 2022

Commission file number: 001-37891

AC IMMUNE SA

(Exact Name of Registrant as Specified in Its Charter)

EPFL Innovation Park
Building B
1015 Lausanne, Switzerland

(Address of Principal Executive Offices)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Yes ☐ No ☒

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Yes ☐ No ☒

On September 26, 2022, AC Immune SA (the “Company”) and Life Molecular Imaging (“LMI”) announced the progression of the Tau PET Tracer PI-2620 into late-stage development in Alzheimer’s disease. The Company is to receive a EUR 4 million milestone payment from LMI for this development.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

AC IMMUNE SA


By:	/s/ *Andrea Pfeifer*
	Name:	Andrea Pfeifer
	Title:	Chief Executive Officer



By:	/s/ *Christopher Roberts*
	Name:	Christopher Roberts
	Title:	Vice President, Finance and Interim Chief Financial Officer

Date: September 26, 2022

EXHIBIT INDEX

Exhibit Number	Description
99.1	Press Release dated September 26, 2022

Dates Referenced Herein

This ‘6-K’ Filing	Date	Other Filings

Filed on / For Period end:	9/26/22	None on these Dates
		List all Filings

↑Top

Filing Submission 0000950103-22-016378 – Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)